🚨 BREAKING: FDA REJECTS SUMMIT (SMMT) LUNG CANCER DRUG
The FDA issued a Complete Response Letter for Summit Therapeutics' ivonescimab plus chemotherapy in previously treated EGFR-mutated lung cancer. The HARMONi trial delayed progression but showed no statistically significant survival benefit — the benefit regulators required.
Summit shares were indicated 20% lower overnight after closing at $14.15 on Friday. Partner Akeso plunged as much as 32% in Hong Kong.
This is news, not financial advice.
📺 Full videos daily on YouTube — subscribe: https://www.youtube.com/@Zimbuckapp
Join the conversation on Zimbuck — the finance social platform for traders & investors: https://zimbuck.com
#SMMT #SummitTherapeutics #FDA #Biotech #Stocks #StockMarket #LungCancer #Investing
The FDA issued a Complete Response Letter for Summit Therapeutics' ivonescimab plus chemotherapy in previously treated EGFR-mutated lung cancer. The HARMONi trial delayed progression but showed no statistically significant survival benefit — the benefit regulators required.
Summit shares were indicated 20% lower overnight after closing at $14.15 on Friday. Partner Akeso plunged as much as 32% in Hong Kong.
This is news, not financial advice.
📺 Full videos daily on YouTube — subscribe: https://www.youtube.com/@Zimbuckapp
Join the conversation on Zimbuck — the finance social platform for traders & investors: https://zimbuck.com
#SMMT #SummitTherapeutics #FDA #Biotech #Stocks #StockMarket #LungCancer #Investing
56 Προβολές